Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry-Reference-Cited by-同舟云学术

Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry

Published:2021-05-11 Issue:8 Volume:100 Page:2043-2050
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Zimmermann Heiner^ORCID,Nitsche Mirko,Pott Christiane,Reinke Petra,Babel Nina,Hermann Robert M.,Hauser Ingeborg A.,Hahn Dennis,Ritgen Matthias,Pietschmann Claudia,Klapper Wolfram,Anagnostopoulos Ioannis,Trappe Ralf U.,

Funder

Roche Germany

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-021-04548-2.pdf

Reference26 articles.

1. Evens AM, Choquet S, Kroll-Desrosiers AR et al (2013) Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Am J Transplant 13:1512–1522. https://doi.org/10.1111/ajt.12211

2. Crane GM, Powell H, Kostadinov R et al (2015) Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget 6:33849–33866. https://doi.org/10.18632/oncotarget.5292

3. Dugan JP, Haverkos BM, Villagomez L et al (2018) Complete and durable responses in primary central nervous system posttransplant lymphoproliferative disorder with zidovudine, ganciclovir, rituximab, and dexamethasone. Clin Cancer Res 24:3273–3281. https://doi.org/10.1158/1078-0432.CCR-17-2685